Compare · CRWD vs ORPH
CRWD vs ORPH
Side-by-side comparison of CrowdStrike Holdings Inc. (CRWD) and Orphazyme A/S (ORPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRWD and ORPH operate in Computer Software: Prepackaged Software (Technology), so they compete in similar markets.
- CRWD is the larger of the two at $170.80B, about 975.4x ORPH ($175.1M).
- CRWD has hit the wire 40 times in the past 4 weeks while ORPH has been quiet.
- CRWD has more recent analyst coverage (25 ratings vs 0 for ORPH).
- Company
- CrowdStrike Holdings Inc.
- Orphazyme A/S
- Price
- $658.72-1.81%
- $0.86-5.49%
- Market cap
- $170.80B
- $175.1M
- 1M return
- +30.27%
- -
- 1Y return
- +41.90%
- -
- Industry
- Computer Software: Prepackaged Software
- Computer Software: Prepackaged Software
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 40
- 0
- Recent ratings
- 25
- 0
CrowdStrike Holdings Inc.
CrowdStrike Holdings, Inc. provides cloud-delivered solutions for endpoint and cloud workload protection in the United States, Australia, Germany, India, Israel, Romania, and the United Kingdom. It offers 19 cloud modules on its Falcon platform through a software as a service subscription-based model that covers various security markets, such as corporate workload security, security and vulnerability management, managed security services, IT operations management, threat intelligence services, identity protection, and log management. The company primarily sells its platform and cloud modules through its direct sales team. CrowdStrike Holdings, Inc. was incorporated in 2011 and is headquartered in Sunnyvale, California.
Orphazyme A/S
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Latest CRWD
- A Next-Gen Intelligence Platform Operating at the Intersection of AI, Defense Technology, and Quantum Cybersecurity
- PRESIDENT AND CEO Kurtz George sold $868,977 worth of shares (1,220 units at $712.28), decreasing direct ownership by 0.06% to 2,137,022 units (SEC Form 4)
- PRESIDENT AND CEO Kurtz George sold $2,760,328 worth of shares (3,780 units at $730.25), decreasing direct ownership by 0.18% to 2,138,242 units (SEC Form 4)
- SEC Form 144 filed by CrowdStrike Holdings Inc.
- SEC Form 144 filed by CrowdStrike Holdings Inc.
- CrowdStrike downgraded by Berenberg with a new price target
- BMO Capital Markets reiterated coverage on CrowdStrike with a new price target
- Needham reiterated coverage on CrowdStrike with a new price target
- SEC Form 10-Q filed by CrowdStrike Holdings Inc.
- Director Gandhi Sameer K sold $1,404,909 worth of shares (1,809 units at $776.62) as part of a pre-agreed trading plan (SEC Form 4)
Latest ORPH
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 20-F filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form NT 20-F/A filed by Orphazyme A/S (Amendment)
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form NT 20-F filed by Orphazyme A/S